Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
February 12, 2026
Earnings Call Speaker Segments
Morgan Sanford
executiveThanks, operator. Hello, everybody, and good morning. We appreciate you being here as we go over the financial results and business highlights from Agios Pharmaceuticals for the fourth quarter and the full year 2025. To follow along with the slides for today's call, head to the Investors section on our site, agios.com. I want to remind everyone that certain forward-looking statements will be made today. Because of a range of risks, uncertainties, and other factors — among them those laid out in our most recent SEC filings and any additional filings we might make with the SEC going forward — actual events and results may differ materially from anything expressed or implied by those forward-looking statements. Joining me on today's call from Agios are Brian Goff, our Chief Executive Officer; Cecilia Jones, our Chief Financial Officer; Tsveta Milanova, our Chief Commercial Officer; and Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development. Once the prepared remarks are done, we'll open things up for questions. With that said, it's my pleasure to hand the call over to Brian.
Brian Goff
executiveAppreciate that, Morgan. Hello, everyone, and thanks for being with us on today's call. Let's go to the next slide. Only last month, we laid out our strategic priorities for 2026, centered on creating long-term shareholder value. To begin, our focus is on delivering a high-impact U.S. launch of Pyrukynd for treating thalassemia. Second, we see substantial opportunity to grow our PK activation franchise into further high-value indications, such as sickle cell disease and lower-risk myelodysplastic syndrome, with important catalysts anticipated this year for both. Third, by moving our early-stage pipeline forward with AG-236 and AG-181, we could unlock future value across hematologic and other rare diseases. Finally, we remain committed to sustainability over the long haul, supported by careful capital deployment and continuous gains in how efficiently we operate. With those priorities as our foundation, the next slide outlines the major pipeline catalysts anticipated for 2026, which cover several opportunities in high-value indications. The U.S. launch of ACTIVASE for thalassemia is already in progress, and we are eager for the chance to extend our PK activation franchise into sickle cell disease as well as lower-risk MDS. Together with ongoing advancement across our early-stage pipeline, these milestones position the portfolio for growth and the creation of long-term value. May we have the next slide, please. We closed out 2025 carrying good momentum across the company — our commercial team's execution, advances in the pipeline, and a continued focus on staying disciplined with our finances. Taken together, those things leave us well positioned to hit the strategic goals we've set for 2026. Starting with commercial results: PYRUKYND brought in $20 million of net revenue in Q4, lifting our total revenue for 2025 to $54 million, which represents strong growth compared with the prior year. During the fourth quarter we also shared top-line results from the phase III RISE UP study, and as expected we'll sit down with the FDA this quarter for our pre-sNDA meeting to chart the regulatory course ahead. One more thing worth noting: right as the year was wrapping up, ACTIVASE received FDA approval, and our U.S. launch in thalassemia is now in progress. To wrap up, enrollment has now closed for our phase II study of tebapivat in sickle cell disease, and we anticipate top-line data during this year's second half. A key point is that we remain in a strong position financially, closing out the year with roughly $1.2 billion in cash. That gives us room to fully support the U.S. launch of ACTIVASE for thalassemia, to determine how to move forward with mitapivat in sickle cell disease, and to keep pushing our pipeline programs ahead. Let's advance to the following slide, where Cecilia will walk us through more specifics regarding our fourth quarter and full year 2025 results, along with what we expect for 2026.
Cecilia Jones
executiveThanks, Brian. Could we move to the next slide? The financial results for our fourth quarter and full year 2025 are available in the press release that went out earlier this morning, and you can find further detail in our 10-K, which gets filed later today. Worldwide PYRUKYND revenue in the fourth quarter came to $20 million, which is up 86% versus the fourth quarter of 2024, and a 55% sequential rise from the $13 million recorded in the third quarter of 2025. Within the U.S., revenues of $16 million for the fourth quarter were fueled by our ongoing commercial emphasis in PK deficiency before FDA approval of ACTIVASE, one extra ordering week during the fourth quarter, and positive growth to net adjustments. For 2026, U.S. PK deficiency revenues are expected to land somewhere between $45-$50 million. Beyond the US, the $4 million in fourth quarter revenue mainly reflects inventory stocking ahead of demand from PK deficiency patients in Europe as they shift from our global managed access program, under which PYRUKYND was given at no cost, over to commercial supply. We expect ex-US revenues to decline sequentially as we enter the first quarter of 2026. Cost of sales during the fourth quarter totaled $1.9 million. R&D expenses reached $88.1 million, up $5.3 million from the fourth quarter of 2024, tied to progress on our earlier-stage pipeline program. SG&A expenses came in at $51.6 million for the fourth quarter, essentially unchanged from a year earlier. We closed the fourth quarter with cash, cash equivalents, and marketable securities of around $1.2 billion. Just a reminder that starting in future quarters, we'll report mitapivat revenue in total, with U.S. and ex-U.S. performance broken out. On to the next slide, please. We stay dedicated to financial discipline as we pursue our aim of turning into a sustainable rare disease company. We expect operating expenses for 2026 to be about level with 2025. That guidance factors in investment to maximize the ACTIVASE launch in thalassemia in the U.S., gated investment for sickle cell disease, and refinement of our operating model. Crucially, we see an obvious route to profitability via our current commercial footprint in thalassemia and PK deficiency. Please go to the next slide, and I'll hand the call to Tsveta for the quarter's commercial highlights.
Tsveta Milanova
executiveThanks, Cecilia. Moving to the next slide. As Cecilia mentioned, PYRUKYND generated $60 million in net revenue within the US during the fourth quarter, representing a 50% increase compared with the same period last year, fueled by ongoing demand in PK deficiency, one extra ordering week during the quarter, and certain gross-to-net adjustments. Revenue outside the US for the fourth quarter came to approximately $4 million, which mainly reflects supply positioned ahead of demand pull-through, as patients with PK deficiency in Europe move over to commercial supply; we anticipate that this ordering will moderate over the coming quarters. As we expected, we continue to observe quarter-to-quarter variability caused by ordering patterns, inventory dynamics, and gross-to-net adjustments. Our Q4 performance demonstrates how well our commercial model works and the base we're creating for upcoming expansion. A key milestone was ACTIVASE's recent US clearance for anemia treatment in adults who have alpha or beta thalassemia, no matter what their transfusion burden looks like. Let's move on to the following slide. Good news to share: the full rollout of PYRUKYND REMS wrapped up as scheduled in late January, bringing it into compliance with the FDA's approved label, and product dispensing is already underway. By January 30, we had 44 prescriptions on record from US physicians certified under REMS — evidence that PYRUKYND's clinical worth is being recognized early and that our field teams have performed exceptionally well. One thing that stands out as really positive is how broad the early prescribing base looks this soon after launch—it's spread well across different regions and, just as we'd anticipated, community-based doctors make up most of those early prescribers. In these first days on the market, we're also starting to see the kind of patient picture we expected: mostly individuals who depend on transfusions, plus a set of highly involved patients who are not transfusion-dependent. What these early indicators tell us goes beyond simply being launch-ready—they also reflect how thoroughly we grasp this patient population and the needs that aren't being met for them. Let's move on to the following slide. The initial market reaction to ACTIVASE has us quite optimistic. In the eyes of physicians, its profile consistently fills significant holes in how thalassemia is currently treated. What's key here is that this matches the feedback we received prior to the FDA's approval. Prescribing isn't being held back by the REMS, based on what we've seen so far, which points to a certification process that has gone smoothly. On top of that, participation in our patient support program has been robust. According to early experience, patients aren't finding the REMS onerous, since the clinical benefits could be substantial — among them fewer transfusions and less fatigue. All of this initial input underscores the considerable unmet need that exists in thalassemia, as well as the value that ACTIVASE offers. This also shows how well we set things up before launch. On the slide that follows, I'll spend a short while explaining how we expect that demand to turn into patients starting treatment and, in the end, into revenues during the first few quarters after launch. The ACTIVASE REMS certification process involves three main steps. Pharmacy education and certification is one of them, and that step is finished already, since we rely on one specialty pharmacy for dispensing prescriptions and for coordinating delivery. In addition, physicians need to complete education and certification for the ACTIVASE brand. Also, once a prescription has been written, patients have to obtain insurance approval and complete a baseline liver test prior to beginning treatment. Our full patient support program, My Agios, has a solid history of helping patients navigate insurance authorization for PK deficiency, and we expect that to carry over to thalassemia. After all three of those steps are done, the pharmacy gets the green light to dispense the prescription. Then patients will do liver tests every month for the first six months, and after that as clinically indicated. At first, we anticipate the period from prescription to treatment start will average 10 to 12 weeks. As more physicians are brought on board and access widens, we see a chance to cut that timeline down as the launch moves forward. Let's go to the next slide. Agios sees thalassemia as a big possible turning point for growth. To date, two regions have cleared mitapivat for thalassemia — marketed as ACTIVASE within the US and as Fyrokind in Saudi Arabia. Thanks to our capital-efficient commercial approach worldwide, we can put our money mainly into the US, since that market holds the largest revenue upside. Outside America, we have struck commercialization and distribution arrangements with Advanz Pharma for Europe and NewBridge Pharmaceuticals for the GCC. Given how access works there, Fyrokind is currently distributed in Saudi Arabia one patient at a time, and there's room to expand availability once national procurement agreements are in place. Across Europe and the UAE, reviews by regulators have yet to wrap up. Following the favorable CHMP opinion we got in October 2025, a decision from the EC could arrive within the next few months. In every one of these markets, we see genuine room to widen access and generate substantial growth as the global rollout ramps up. Let's move on to the following slide, and at this point I'll hand things over to Sarah, who will walk through the main R&D developments of the quarter.
Sarah Gheuens
executiveThanks, Tsveta. Let's go to the following slide. Since the time we announced our third quarter results, we've kept moving forward in advancing our strong rare disease pipeline. On December 23 of last year, we obtained FDA approval for PYRUKYND in alpha and beta thalassemia, irrespective of transfusion burden. As Tsveta told you, the US launch is now happening, and physicians have responded very favorably. After the RISE UP phase III top-line data for mitapivat in sickle cell disease, our pre-sNDA meeting will take place this quarter to guide the regulatory path ahead; we keep pushing forward our more potent PK activator, tebapivat, across two phase II trials, and we expect results in lower-risk MDS during the first half of this year and in sickle cell disease during the second half. We're continuing to move our early-stage pipeline toward key decision points this year, and we remain on schedule to begin a phase Ib proof of mechanism trial of AG-181, our phenylalanine hydroxylase stabilizer for PKU patients, within the next few months, and to report top-line data from the phase I healthy volunteer study of AG-236, our siRNA aimed at TMPRSS6 for polycythemia vera, in the first half. Please turn to the next slide. Now on tebapivat, we're eager to learn more this year about what role this more potent PK activator might play in low-risk MDS and sickle cell disease. We remain on schedule in low-risk MDS, where top-line data from the phase IIB trial should arrive in the first half of this year. This study will yield valuable insights into dose optimization, along with the possible role of tebapivat across different patient subgroups, such as those with low and high transfusion burden, plus possible uses in later lines of treatment; in sickle cell disease, enrollment in the phase II trial has now finished, a key milestone that shows the rising enthusiasm for PK activation after the RISE UP phase III results of mitapivat in this debilitating and deadly disease. This 12-week double-blind trial is intended to further explore tebapivat's potential to produce meaningful gains in hemoglobin, as well as broader markers of hemolysis. In turn, we see the possibility of a higher hemoglobin response, building on the strength of the data established with mitapivat. Taken together, these programs highlight tebapivat's potential to broaden our leadership in hematology and serve multiple high-value populations where unmet need remains significant. We have an exciting year ahead, and we look forward to updating you on our pipeline progress throughout the year. With that, please turn to the next slide, and I'll hand the call back to Brian for closing remarks.
Brian Goff
executiveThanks, Sarah. Turning to the next slide — to wrap up, another year full of pivotal catalysts lies ahead of us. Consistent with the strategic priorities we've set for 2026, our attention is on pulling off a high-value US launch of ACTIVASE in thalassemia. On the sickle cell disease side, this quarter we're getting ready for our pre-sNDA meeting for mitapivat, a significant milestone on the way to nailing down our regulatory path. Later this year, we also anticipate phase II top line data for tebapivat in sickle cell disease, which should deepen our understanding of what higher potency PK activation could mean for this population. When it comes to lower-risk MDS, phase 2b top line data for tebapivat are still on schedule for the first half of 2026, and that will be a key readout as we evaluate how well it drives transfusion independence along with broader anemia improvements. We likewise look forward to phase I top line data for AG-236 in polycythemia vera, plus phase 1b proof of mechanism data for AG-181 in PKU — two significant early-stage programs that widen our reach across hematologic and other rare diseases. Kindly advance to the following slide. Looking past 2026, the opportunities available to us keep growing. Across the indications in our current pipeline, combined global market potential is above $10 billion, which speaks both to how much unmet need exists and to our ability to bring transformative medicines to patients. Starting in 2026, our focus is on delivering a high-impact US launch of ACTIVASE and thalassemia, something we think can lay a strong foundation for our leadership more broadly in rare hematology. Near-term catalysts, disciplined investment, and a maturing pipeline together create an obvious route to long-term value. Agios stands well positioned for the coming chapter of growth as we push forward the next wave of innovation throughout our rare disease portfolio. Ahead of moving into Q&A, I want to recognize our employees' dedication — their unwavering focus and commitment keep making a meaningful difference for patients living with rare diseases. With that, I'd like to open the call for questions. Operator, please open the line.
Gregory Renza
analystFantastic. Thank you. Morning to you, Brian, and everyone on the team. Congratulations on the quarter and, naturally, on yet one more action-packed year. We might have a couple of questions, first regarding ACTIVASE and then regarding sickle cell. To start, about the ACTIVASE launch, we're grateful for all the detail you're providing this early and for the work to get patients involved and prescriptions written. On that translation point, maybe with respect to the prescription updates we're observing, in what way do you expect that to convert not just into treatment initiation but also into revenue recognition? Perhaps I'm not requesting guidance on the early quarters, but whatever detail you can offer on the first quarter and even the subsequent early days of the launch concerning how it lifted revenue. Then I have a follow-up. Thank you.
Brian Goff
executiveYes. Thank you, Greg. I'm very glad to discuss the launch. And before Tsveta starts in here, I simply want to state that I feel a great deal of pride in how the team has carried out its early days, but Tsveta is delighted to at last have an opportunity to start speaking about the ACTIVASE launch.
Tsveta Milanova
executiveSure thing. I'm definitely thrilled. Greg, like I said during my prepared remarks, the early demand we're seeing for ACTIVASE has us quite encouraged. As you pointed out, we shared that we had 44 prescriptions from physicians certified through REMS as of January thirtieth — that covers the launch's first five weeks — and it's wonderful to witness. On your questions, what we anticipate during the opening quarters is that prescriptions and demand will climb faster than revenues, and the primary explanation is that converting prescriptions into treatment initiations and, in the end, revenues takes roughly 10 to 12 weeks for us. During Q1, we expect most of those prescriptions to become treatment initiations, and later in the year, revenues and demand should begin moving in closer alignment. A great deal of inquiry comes our way regarding possible analogs. When I consider a different product that likewise carries a liver REMS — namely Filspari — that one makes a solid analog for you to examine, showing how the real revenue trajectory unfolded across the launch's first year. Naturally, it's a completely different disease, yet when it comes to the revenue curve's shape, I believe it, it's worth a look.
Gregory Renza
analystExcellent. I appreciate that; it's quite useful. Perhaps we can now turn to sickle cell and tebapivat, and naturally, we shouldn't ignore the MDS readout in the first half; however, given that enrollment is finished in the phase two sickle cell trial and Sarah, the color that you've provided, maybe I could ask a little about how you're setting expectations for what you'd like to observe to feel excited about the phase two sickle cell data arriving later this year. You've discussed the potency and the greater hemoglobin response potential, but any color that would assist in getting you excited and how that sort of fits into the broader portfolio compared with mitapivat and the wider sickle cell space even. Many thanks, and congratulations once more, everyone.
Brian Goff
executive... Thanks, Greg. Sarah?
Sarah Gheuens
executiveThanks, Greg. Yes, I appreciate the question, Greg. So the phase 2 tebapivat study, whose full enrollment we just announced, is designed to find the right dose, so we're indeed aiming to investigate dosing levels; we're evaluating hemoglobin response. This is a standalone phase 2 study, meaning our VOCs serve as safety measures. That differs from how the phase 2/3 seamless operational design worked for RISE UP. But clearly, we're now able to draw on data throughout the PK activation franchise, essentially, and we can apply RISE UP findings to model what we expect a hemoglobin response might mean for clinical benefit. So we're really enthusiastic about this study; we believe the fact that we can report enrollment completion also shows how excited the community is. You know, the RISE UP data release truly drove quicker enrollment into the tebapivat phase II trial, so that's something we're very thrilled about.
Samantha Semenkow
analystHello there, good morning, and I really appreciate you fielding these questions, plus congratulations on everything you've achieved commercially. I just have one quick follow-up regarding ACTIVASE. Could you perhaps discuss a little about how prescription volumes have trended since the approval came through, and in particular, have you noticed more prescriptions being written starting January 30th, once the REMS was up and running at full capacity? Then my second item: might you address what possible results could emerge from the scheduled sNDA discussion with the FDA concerning sickle cell disease? What kinds of outcomes might arise from that sit-down? Many thanks.
Brian Goff
executiveThank you, Sam. We'll stay with the 44 figure we've reported thus far for ACTIVASE, though I believe Tsveta can keep offering perspective on, you know, those initial launch days. So I'll ask Tsveta to begin there, and after that Sarah is able to address the pre-sNDA meeting.
Tsveta Milanova
executiveOf course, Sam, and just to note, we began essentially getting physicians involved and informed, as well as building demand, right when the product received approval. So during the initial five weeks following launch, we've been teaching doctors about the value proposition of ACTIVASE and the REMS program itself; therefore, we're quite encouraged by what we're observing regarding demand in these early launch phases. Many of the developments — and I'm genuinely, genuinely happy with how the team has executed — are unfolding just as we anticipated; consequently, we're seeing prescriptions originate from transfusion-dependent patients as well as the highly engaged, symptomatic, non-transfusion-dependent patients who interact frequently with the healthcare system, which is wonderful. And we're observing very healthy launch dynamics when it comes to prescribing physicians; we're seeing prescriptions arrive from all over the country, and many of those are in the community setting, where most patients receive treatment, and I'm truly pleased with the headway the team is achieving.
Brian Goff
executiveGreat; and then, Sarah, the pre-sNDA meeting and Sam's question about the potential outcomes.
Sarah Gheuens
executiveYes, thank you, Sam. We have given guidance about that pre-sNDA meeting happening during the first quarter of this year. What we aim to accomplish there is, naturally, obtaining insight into the regulatory routes available to us for mitapivat. As we mentioned, we will of course arrive with a data package we intend to submit seeking full approval, drawing on the data produced in RISE UP, including that robust anti-hemolytic profile which once again confirms mitapivat's anti-hemolytic profile, this time in a third hemolytic anemia, along with further strong clinical benefit seen among those hemoglobin responders. And after that meeting takes place, we plan to provide an update, or once the meeting minutes are available, we'll share them with all of you.
Samantha Semenkow
analystGreat. Thanks very much.
Brian Goff
executiveThank you.
Alec Stranahan
analystHi, everyone. Appreciate you fielding our questions. It's really encouraging to watch the momentum build across the commercial side and the clinical stage assets. We've got a couple of things to ask. So first off, when it comes to creating that 10- to 12-week window between a prescription being written and treatment actually starting, where's the biggest logjam? Does it come down to scheduling the patient for their baseline liver test, or is there another factor? And what kind of reduction do you expect to see as this year goes on? Then for the second one, regarding tebapivat in MDS, what would you consider a strong result for transfusion independence among this lower-risk group? And also, based on takeaways from the phase IIa, do you think activity could show up at the 10 mg dose, given the PK data that's starting to emerge, or does that seem more probable at the 15 and twenty mg doses? Thanks so much.
Brian Goff
executiveAppreciate it, Alec; we'll keep the same order as before. Tsveta will cover the ACTIVASE launch, and then Sarah — it's a good thing we've got such a deep pipeline — can walk through the tebapivat MDS trial.
Tsveta Milanova
executiveSure. Two factors explain that 10 to 12 weeks. Insurance authorization comes first, and it's quite typical for any drug treating a rare specialty disease. That isn't something specific to ACTIVASE. On top of that, the majority of patients would have to clear prior authorization, a step that typically runs about a month, though certain patients move through it more quickly. Others take more time, yet this remains among the primary causes. The second factor involves needing a liver test before treatment begins; putting these two elements together, we expect the average gap between a prescription being written and treatment starting to run 10 to 12 weeks. As I mentioned, patients will land at either end of that window. And with time, we'll naturally aim to reduce that prescription-to-treatment-initiation period on both fronts. Our market access team is outstanding and will work with payers. So once certain payers place the product on formulary, that gives us a chance to speed through some prior authorizations and patient support, and we'll also be learning across the launch and pinpointing ways to help patients get their liver testing done efficiently from the start.
Brian Goff
executiveThanks; and Sarah, regarding tebapivat for MDS, could you share a bit of, well, what should we be anticipating? And then the various dosing as well.
Sarah Gheuens
executiveYes, thank you, Alec. Regarding what you mentioned, we are in fact evaluating larger doses than the one studied during phase 2a. That means we have doses of 10 milligrams, 15 milligrams, and 20 milligrams. So in this phase II, we truly intend to investigate these doses to determine which one works best. Furthermore, since this is a patient group with varied characteristics, the study will let us better characterize those populations. We therefore have low and high transfusion burden, along with other therapy lines that patients have received; this should provide substantial insight into the areas where this drug may be useful. Clearly, being an oral treatment, that can be quite significant for a group of patients such as this, since, should patients achieve a treatment response, it lets them become truly free from the clinic.
Brian Goff
executiveSo yes, this is going to be... it's a thrilling stretch ahead for tebapivat. During 2026, there are 2 catalysts on our radar. As we pointed out, the MDS phase 2B trial lands in the first half of the year, and after that, which we've talked about already, on the sickle cell disease side, in the back half of this year, we're eager for that phase II readout.
Alec Stranahan
analystExcellent. I appreciate the additional detail, and nice work on the ongoing momentum, everyone.
Brian Goff
executiveThanks.
Mark Breidenbach
analystHello, and thank you for taking my question — actually, my questions. Perhaps we could begin with ACTIVASE and the REMS-certified physicians. Could you possibly describe, from a quantitative standpoint, where things stand during these initial months? And what do you expect that trajectory to look like regarding the number and breadth of certified physicians across the coming quarter or two, as that portion of the ramp truly takes hold? Then I have a follow-up regarding the pipeline.
Brian Goff
executiveAll right, feel free to begin.
Tsveta Milanova
executiveYes. Regarding the REMS, at this early point in the launch, what we're observing makes me quite happy, and everything is unfolding just the way we expected. For physicians, the REMS isn't viewed as an obstacle to prescribing, and among the patients we've interacted with, it essentially isn't perceived as a hassle, because of how compelling the value proposition of ACTIVASE is and their readiness to think about and begin treatment. So what's going on with the REMS? At first, many of the larger academic centers and care worlds are completing certification, and as for community physicians, the actual certification occurs nearly at the same time as the first prescription. And in a sense, we'll observe certification and the REMS moving forward at the same time as time goes on. Yet as I mentioned, the REMS has not been a cause, or a cause for declining to prescribe. It's quite the reverse. When physicians have patients they wish to initiate, they are extremely willing to begin filling out the REMS, which in fact can be done in a single visit; the process is very fast.
Mark Breidenbach
analystOkay, thank you, that helps a lot. So to build on what Sarah said regarding the meeting before the sNDA, and the fact that this package is truly designed to back full approval — at other points, I believe you've brought up the chance of getting accelerated approval as an outcome. Do you still view that as a sensible possibility, or have you grown more sure about full approval than you might have been now that you've gone a bit further into the data and the conversations? And if accelerated approval is indeed still possible, then what are your current views on how a confirmatory trial could be shaped in that case?
Sarah Gheuens
executiveYes, thank you, Mark. So from our perspective, the data package—the benefit-risk profile that came out of RISE—actually supports a strong anti-hemolytic profile, like I said, and we truly observe those clinically meaningful shifts among the hemoglobin responders. So our position is that the benefit-risk here is, you know, demonstrated in this study, and this is a supplemental NDA. Now, as you're also aware, at ASH recently, the FDA emphasized that hemoglobin may serve as a surrogate endpoint for sickle cell disease. So either of those routes available to us lets us talk through the data and hold that meaningful discussion with the agency under either set of circumstances; beyond that, there are always the standard filing processes one would need to complete. But we're quite enthusiastic about the data as it currently stands. As for your question about confirmatory trials, clearly we have a number of options we can talk about, and some of those options involve endpoints that have previously been used. A few of them are novel endpoints too, so we're prepared to discuss whenever needed.
Mark Breidenbach
analystAll right, thanks.
Eric Schmidt
analystHi, everyone. Apologies if you can hear anything in the background, but Cecilia brought up a direct path — or clear path — to profitability. I was hoping you might share a bit more detail about your thinking on the revenue breakeven point required to reach that, and perhaps the timelines for getting there. Also, did you make any sales at all in the GCC countries during Q4? Thanks.
Cecilia Jones
executiveThanks, Eric. Our profitability guidance covers PKD and thalassemia, no matter how things go with sickle cell. That's roughly our base case. We haven't provided a specific timeline for when it will occur. We think thalassemia represents a meaningful opportunity; the early launch stages have us excited. As you noted, ex US is also part of that opportunity; and reaching profitability also means we need to proactively manage our OpEx while steering through the many pipeline catalysts. We discussed tebapivat, and we also have our earlier programs, so we haven't given specific timing on that. My mistake. Second.
Brian Goff
executiveRegarding the GCC?
Cecilia Jones
executiveNow, when it comes to the GCC, what we have observed is that the revenue outside the US that showed up in Q4 was largely a result of Europe, and this happened because of anticipated demand, which explains our guidance toward a decline expected from Q4 into Q1. As a reminder, the GCC at present operates under something similar to a named patient arrangement, handled on a case-by-case basis, so you will notice a degree of steadiness from one quarter to the next until we reach a stage where broader access has been negotiated across roughly the coming 12 to 18 months.
Brian Goff
executiveYes, Eric, let me jump in on that. We feel good about the partnership we've established in the GCC with NewBridge. Tsveta and I were in Saudi Arabia toward the end of last year, and we gained a real on-the-ground view of how the team is performing, the excitement coming from clinicians, and even at the level of the Minister of Health. Obviously, building traction will require time, but at this early stage, we're feeling pretty positive about what's possible.
Eric Schmidt
analystThank you.
Brian Goff
executiveYou bet.
Emily Bodnar
analystMorning, and thanks for fielding our questions — really impressive momentum you've built. First, could you describe which kinds of doctors are writing the earliest Activase scripts? Are these mostly people who previously prescribed PYRUKYND, or are you seeing clinicians who are relatively unfamiliar with the drug? Then, turning to sickle cell disease, if you do reach alignment with the FDA, should we expect a possible approval during 2026? Also, could you walk through any launch preparation planned for this year before that approval comes? Thanks.
Brian Goff
executiveAppreciate it, Emily. Tsveta, would you like to kick things off regarding ACTIVASE and who the prescribing physicians are in these early days?
Tsveta Milanova
executiveCertainly. Like I mentioned, many of the initial launch trends are unfolding just as we anticipated. Ahead of the launch, the team performed an excellent job with account profiling and prioritization, so the first prescriptions are in fact being written by the doctors we expected would prescribe. As I noted, Emily, these are mainly community hematologists, who see the majority of patients, and they are physicians we have worked with before. We don't observe a great deal of overlap between PK deficiency and thalassemia, since PK deficiency is an ultra-rare disease, meaning very few doctors truly have experience with PYRUKYND from treating PK deficiency; and as I stated, the beginning of this launch pleases me greatly; we're seeing a very healthy breadth of prescribing nationwide. Various physicians are involved and are genuinely testing the product in the patients they believe will benefit most at first.
Brian Goff
executiveGreat; and Sarah, for sickle cell disease and-
Sarah Gheuens
executiveYes.
Brian Goff
executive-potential timing.
Sarah Gheuens
executiveCorrect. So Emily, we haven't provided any guidance on possible approval timelines up to this point; the initial guidance we've offered during this process is our pre-sNDA meeting, which we expect in Q1. And as for getting ready for launch, I'll have Cecilia weigh in.
Cecilia Jones
executiveRight, just to remind everyone, we didn't — much like what we did with thalassemia — we didn't build for sickle cell until we saw the data, and that's what we mean when we mention the gated sickle cell investments. We'll examine that timeline and figure out the path to begin building investment there accordingly.
Analyst
analystMorning. Lydia here, filling in for Salveen. We really appreciate you taking our questions, and congratulations on the updates. Could you share any further detail regarding how those 44 prescriptions break down between patients who are non-transfusion-dependent and those who are transfusion-dependent? Also, since prescriptions will be the main metric everyone watches, do you expect third-party services such as IQVIA to pick these up accurately? Many thanks.
Brian Goff
executiveTsveta?
Tsveta Milanova
executiveRight. So the first scripts, like I mentioned, are pretty much in line with what we expected, coming from a mix of transfusion-dependent patients. Clearly, a big share are transfusion-dependent, plus highly engaged symptomatic non-transfusion-dependent patients who are actively interacting with the healthcare system. So if you think about how this evolves over time, as we anticipated, I think early on we'll see more transfusion-dependent patients, but the ramp of the launch will come later from the non-transfusion-dependent patients. As for IQVIA, we have one specialty pharmacy distributing the product, so IQVIA won't be the right source for you to look at. The information simply won't be there, and that's why we're looking to give you prescriptions and revenue initially, and we also gave you the guidance on PK deficiency, so you can see where thalassemia growth will come from during the year.
Analyst
analystThank you very much.
Tessa Romero
analystHi, everyone. We appreciate you answering our questions today. The first item concerns Activase. Could you briefly discuss how payers have behaved initially across the first 2 quarters, and also remind us about the payer mix? We just want to confirm we're approaching the possibility of free drug correctly. Then, a second item, somewhat of a housekeeping one. Assuming approval comes through in sickle cell disease, what happens to your SG&A line? We're simply attempting to reason through what would be required to launch a drug successfully in sickle cell, from the standpoint of expenses. Many thanks.
Brian Goff
executiveAll right. Tessa, thank you; and Tsveta is able to begin with the payer side, and perhaps we might additionally remind everyone of our gross to net assumptions as well. I don't believe we-
Tsveta Milanova
executiveRight. Of course. So, Tessa, let me begin there. The payer mix for thalassemia looks a lot like what we see in PK deficiency, and most patients fall into the commercial payer category. That's very much like PK deficiency with any other drug. At first, getting actual market access and payer authorization will come through medical exceptions, since payers need time — roughly 6 months, 6 to 9 months — before they actually begin placing the product on formulary. Our market access team is highly experienced and knows well how to work through the medical exceptions process, and up to now, in these early launch days, I have to say, just as we expected, we've encountered no payer hurdles whatsoever. The value proposition of ACTIVASE, I think, speaks for itself, and the team is performing excellently when it comes to those interactions. Brian wanted me to address the gross to net ex assumptions. Since we don't anticipate this being a managed category, with a payer mix very much like PK deficiency, or gross to net net assumptions for thalassemia comparable to PK deficiency, 10%-20%.
Cecilia Jones
executiveTurning to what you asked about SG&A, Tess — the way we’re approaching it is that, as I said, how much we spend will be calibrated and steered by the regulatory talks and their timing. If you’re trying to frame it, though: the infrastructure we’ve put in place for PKD and thalassemia is something we would clearly take advantage of, yet sickle’s scale is far larger, which means those functions we established would need to be scaled up — although the foundation we can build on is a really solid one.
Tessa Romero
analystThank you.
Brian Goff
executiveThank you.
Analyst
analystOh, that's wonderful. Hey there, everyone; Shelby here, filling in for Luca, and I appreciate you fielding this. Would you mind walking us through the reasoning behind using a larger dose in lower-risk MDS compared with the phase II trial in sickle cell disease? Then perhaps one additional item; since we now have the label along with the REMS program for thalassemia, are you anticipating any read-through to sickle cell, and has that shifted any in-house views regarding the commercial opportunity in that area? Any detail would be greatly valued. Thank you.
Brian Goff
executiveYes, I believe we could begin with MDS and the reasoning for each of the three dose levels exceeding what we studied in the 2A, and after that we'll spend a bit of time on REMS and sickle.
Sarah Gheuens
executiveRight, so regarding why we went with larger doses: initially, we ran a phase 2A using 5 milligrams, which came from modeling done on the healthy volunteer study. But what that study showed us is that people with MDS break the drug down more quickly. Because of that, in phase 2B we increased the amount to explore the dose further, unlike in sickle cell disease, where patients behave just like healthy volunteers. That explains the difference in dosing you see across those two indications.
Brian Goff
executiveAfter that, Sarah, you might kick things off regarding sickle cell — the REMS and read-through topic — and Tsveta is definitely able to weigh in on our commercial perspective.
Sarah Gheuens
executiveRight. So, as you're aware, with the sickle cell disease program, our findings weren't the same as those in thalassemia. It's far closer to what we saw with pyruvate kinase deficiency, where there's no REMS, as you know, unlike thalassemia, which does have a REMS. All of that genuinely provides us with optionality. Given the data we've observed, our starting assumption is that it wouldn't be required, and we'd put forward something along the lines of the pyruvate kinase deficiency approach. Now, regarding a read-through, should a REMS turn out to be necessary, I'll pass that question to Tsveta.
Tsveta Milanova
executiveSure. Clearly, sickle cell disease is a terrible condition marked by significant illness and death, with no therapeutic choices, so we perceive a substantial business opportunity, provided we secure a US label, and the team will be prepared to deliver on that. We have prepared for and are carrying out the REMS for thalassemia effectively. That provides us a really strong basis to keep delivering, should we end up with a comparable situation in sickle cell disease too.
Brian Goff
executiveRight, and I want to take just a second to mention that Tsveta’s group has kept steering their way through the PKD launch, which is extremely uncommon and definitely not the simplest launch, one that got underway in 2022. And at this point we’ve got PYRUKYND getting off to, you know, a genuinely strong beginning during January’s first month. So I feel quite sure that the team, under any circumstances, is going to be extremely well ready. So I believe that was our final question?
Brian Goff
executiveAll right. So with that, I'll bring things to a close. First off, I'd like to express my gratitude to each of you for being here this morning. This is a thrilling moment for Agios. As has been mentioned during the call, we are stepping into 2026 carrying considerable momentum, and we're genuinely encouraged that early progress with the PYRUKYND launch in the US is already looking strong. Significant clinical and regulatory milestones lie in front of us, as we've discussed, and we will keep running the business with a focus on financial discipline. Taken together, these near-term catalysts and our pipeline as it advances put Agios in a position to achieve ongoing growth and value over the long term, and we're truly grateful for your continued involvement and eager to bring you updates on how we're doing across the year. Many thanks.
Operator
operatorWe appreciate it; that brings today's conference call to an end. Thanks for joining us, and at this point you're free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.